Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQCPXL)

• Drug Name: AR-C118925XX Drug Info
• Synonyms: AR-C118925

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 54210200
  TTD Drug ID: DMQCPXL

Molecule-Related Drug Atlas

Drug(s) Targeting P2Y purinoceptor 2 (P2RY2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diquafosol	DM64QG9	Dry eye disease	9E1Z	Phase 3	[3]
INS-37217	DMF93RQ	Cystic fibrosis	CA25	Phase 2	[3]
INS 316	DMTHMEI	Lung cancer	2C25.0	Discontinued in Phase 3	[4]
PSB-0963	DMBDVJ1	Discovery agent	N.A.	Investigative	[5]
RB 2	DMCEFUW	Discovery agent	N.A.	Investigative	[6]
UTPgammaS	DMKLB4O	Discovery agent	N.A.	Investigative	[7]
Acid blue 25	DMCU6XV	Discovery agent	N.A.	Investigative	[5]
5BrUTP	DMEVRH4	Discovery agent	N.A.	Investigative	[7]
2-thioUTP	DMJZ5V0	Discovery agent	N.A.	Investigative	[8]
SB-416	DMJW72O	Discovery agent	N.A.	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2Y purinoceptor 2 (P2RY2)	TTOZHQC	P2RY2_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5907).
• [2] Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2004 Oct;31(4):446-55.
• [3] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [4] Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol. 2001 Aug;32(2):122-8.
• [5] Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
• [6] Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7.
• [7] Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27.
• [8] Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87.